Tadalafil Tablets Recalled Due to Manufacturing Practice Violations
Northwind Pharmaceuticals is recalling 23 bottles of Tadalafil 5 mg tablets nationwide due to manufacturing process deviations. The FDA classified this as a Class II recall.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification indicates potential for adverse health consequences. CGMP deviations represent manufacturing process failures that could affect product quality and safety. While no illnesses or injuries have been reported, the product poses a risk of harm, fitting the rubric criterion for 'risk-of-harm products where injury has not yet been reported.'
Plain-English summary
Northwind Pharmaceuticals LLC has issued a voluntary recall of Tadalafil Tablets, USP 5 mg, in 30-count bottles. The recall affects 23 bottles distributed nationwide with lot number F114302001 and an expiration date of May 31, 2023.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified at the manufacturing facility. CGMP violations indicate that the product was not manufactured according to FDA standards for quality and safety.
Patients who received this medication should consult with their healthcare provider or pharmacist to determine if they have been affected by this recall. The medication should not be used if it bears the recalled lot number and expiration date.
Consumers with questions or concerns about this recall should contact their pharmacy or healthcare provider. No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Northwind Pharmaceuticals LLC
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: F114302001
- Exp. Date 05/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TADALAFIL
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- ModerateTadalafil tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil tablets recalled for manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27